Applications of 1,3,5-Tri-O-Benzoyl-D-Ribofuranose in Industrial Manufacturing

1,3,5-Tri-O-Benzoyl-D-Ribofuranose serves as a critical protected sugar intermediate for nucleoside and nucleic acid synthesis. Our in-factory synthesis quality is dedicated to high-purity demand from pharmaceutical, diagnostic, and biotechnological sectors. Below we detail several specific downstream applications, regulatory frameworks, and product integration flows for industrial customers.

1. Nucleoside Active Pharmaceutical Ingredient (API) Synthesis

In pharmaceutical manufacturing, this compound is a crucial protected intermediate in the synthesis pathway for antiviral and anticancer nucleoside APIs. During glycosylation, it protects the hydroxyl groups—enabling specific attachment of nucleobases and controlled deprotection. Major end uses include APIs for cytarabine, vidarabine, and related agents, where repeated purification and validation are required to ensure pharmaceutical purity. Our product quality supports long multi-step reactions, minimizing side reactions and batch rejections.

Industry compliance standards

• ICH Q7 for Good Manufacturing Practice (GMP) of APIs
• United States Pharmacopeia (USP) standards for API intermediates
• European Pharmacopoeia (Ph. Eur.) for nucleoside building blocks
• 21 CFR Part 211 (US FDA cGMP regulations)

Typical usage ratio

• 1.0 to 1.2 molar equivalents relative to target nucleobase per batch
• Ratio may be adjusted based on glycosylation efficiency and base reactivity
• Used in slight excess for high-purity protocols
• Final ratio optimized after pilot reaction QC

Downstream process integration

• Added during early-stage glycosylation step of nucleoside API synthesis
• Processed in controlled temperature and solvent system for benzoyl group protection
• Deprotection (hydrolysis or transesterification) occurs after nucleobase coupling
• Product advanced to next purification and intermediate validation stage

Final product types

• Antiviral nucleoside APIs (e.g., cytarabine, vidarabine)
• Anticancer chemotherapeutics
• Clinical grade nucleoside analogues
• Bulk intermediates for global drug formulation

2. Diagnostic Oligonucleotide Manufacturing

Industrial production of DNA and RNA oligonucleotide probes relies on protected ribofuranose derivatives for nucleotide building blocks. This material supports automated synthesizer platforms and controlled deprotection schedules. It is essential during phosphoramidite coupling steps, reducing byproduct incorporation and ensuring high sequence fidelity for molecular diagnostics, PCR kits, and research probes.

Industry compliance standards

• ISO 13485 for medical device and diagnostic reagent manufacturing
• ISO 9001 quality management for biotechnological production
• FDA regulations for analyte specific reagents (ASRs) in diagnostics
• International Council for Harmonisation (ICH Q9, Q10) for quality risk management

Typical usage ratio

• One equivalent per protected nucleotide unit on automated synthesis columns
• Ratio fine-tuned per run to balance yield vs. synthesis speed
• Multiple cycle use for short (10–30mers) and long (>50mers) oligonucleotides
• Monitored by in-process HPLC or mass spectrometry

Downstream process integration

• Incorporated at ribosylation stage of phosphoramidite synthesis
• Benzoyl group enables programmed removal after oligonucleotide chain assembly
• Purification downstream uses reverse-phase and ion-exchange chromatography
• Material wastes neutralized by validated effluent processes

Final product types

• Synthetic DNA and RNA probes
• Real-time PCR and qPCR kits
• Gene synthesis blocks
• Next-generation sequencing (NGS) sample prep reagents

3. Custom Carbohydrate Derivative Manufacturing

The selective protection pattern of this benzoylated ribofuranose enables synthesis of specialty carbohydrates for pharmaceutical excipients and biochemical substrates. Chemists use it for divergent glycoside synthesis, producing custom monosaccharide and oligosaccharide molecules for research, vaccine adjuvants, and enzyme substrates, with consistent reproducibility across kilogram batches.

Industry compliance standards

• ICH Q11 for drug substance development and manufacture
• ISO 9001 for chemical synthesis and QC documentation
• GMP standards where carbohydrates enter regulated formulations
• REACH registration for supply to the EU chemical market

Typical usage ratio

• 1.0 molar equivalent per glycosylation acceptor/substrate
• Adjustable excess (up to 1.5x) to drive reaction completion in difficult couplings
• Used at batch scales from 100 g to 100 kg
• Ratios selected based on acceptor and reaction solvent compatibility

Downstream process integration

• Activated during glycosylation steps for targeted carbohydrate modification
• Protection facilitates sequential deprotection for regioselective synthesis
• Integrated purification using preparative chromatography or crystallization
• Final degradation and impurity clearance performed under QC audit

Final product types

• Pharmacopeial carbohydrate excipients
• Complex vaccine adjuvants
• Analytical enzyme assay kits
• Novel glycosylated research chemicals

4. Advanced Nucleic Acid Analogue Production

This protected ribofuranose is vital in synthesizing nucleic acid analogues with altered sugar backbones for gene‐editing, antisense oligonucleotide therapeutics, and research tools. Benzoylation provides selectivity for introducing modifications such as 2′-O-methyl or 2′-fluoro groups. Downstream manufacturers depend on consistently pure material for complex multi-step synthesis with strict profile validation.

Industry compliance standards

• GMP manufacturing (21 CFR Part 210/211 for APIs and advanced intermediates)
• USP General Chapter <1045> on Biotechnology–Gene Therapy Products
• ICH Q3A/B for impurities and residual solvents
• ISO 18385 for forensic DNA-grade manufacturing

Typical usage ratio

• 1.0 to 1.3 molar equivalents, based on target analogue and sugar modification strategy
• Up to 1.5x for challenging 2′ substitution reactions
• Scale runs from mg R&D to multi-kilogram commercial batches
• Optimized after analytical yield and by-product analysis

Downstream process integration

• Used in protected sugar-synthesis steps for modified nucleotides
• Diversified functionalization after benzoyl group removal
• Analytical testing by NMR and HPLC at each critical step
• Final products isolated after preparative HPLC or crystallization

Final product types

• Antisense oligonucleotide APIs
• Gene-editing nucleotide monomers
• Diagnostic-grade nucleic acid analogues
• R&D grade modified ribonucleotides